Showcasing the recent developments of TSXV:NRX , will be upgrading on the OTC very soon which should help the volume. Currently holding the 200MA.
VINC was a penny stock and is now in the near penny category as this biotech stock has had a great run in the past 10 days. On the 30 minute chart, 225 shares are bought at low prices and 125 shares are sold for profit with 100 shares still running as the momentum slows. Overall, the trades where profitable averaging 12% daily in an average trade of 4.5...
Wuxi Biologics (2269): HKEX:2269 Wuxi Biologics, a Chinese biotech research company listed on the Hong Kong Stock Exchange, presents a complex investment scenario. It's crucial to note we're dealing with the Hong Kong Dollar, not the US dollar. The comprehensive analysis on the weekly chart suggests that since June 2021, the company has been undergoing a...
VINC went from 1.5 to 3.0 in less than three hours with 12X relative volume in the afternoon after a month of a slow climb from a news release that really did not amount to much. Insiders are 25% of the shareholders and that may be the story here. This could be manipulation at its finest. I have to wonder how many insiders bought how many shares and when the...
Positive news on phase 3 trials. Possible US food & drug admin application next year 2025 8.5 times the usual 20 daily volume average. Red to green reversal. This all points towards likely higher prices. If their application next year gets approved expect a monster move. Investors will likely try to front run this.
Quantum-Si NASDAQ:QSI , develops access to the proteome with single-molecule analysis and democratizing to researchers & clinicians Also, "is the world’s first-to-market provider of protein sequencing instruments with core technology based on proprietary time-domain sequencing that enables resolution of amino acids during experiments".- Ark Invest The stock is...
At some point there will be a boom biotechnology stocks. They haven't done much in the past ten years. I believe IBB will pass 250 within the decade. However, if the market remains stable, without any 20%+ corrections, I think IBB hits 250 to 300 in the next year
📊 Analysis NASDAQ:BPMC : Financial Performance: 90% YoY growth in net-product revenues from U.S. sales of Ayvakit, a drug for certain cancers. Market Prospects: Positive market response to Ayvakit's unique clinical profile. CEO's Confidence: CEO's confidence in the company's future contributes to its momentum. 📈 Bullish Sentiment: Entry Range: Suggested entry...
NRIX , on the 15 minute chart is experiencing increase volatility and volume now two days out from its earnings report. It printed a "big ass" green engulfing candle to finish the week. The MACD with zero lag shows a bullish inflection in the lines On the daily chart, price fell about 25% in 2023. earnings have been both line beats but the negative cash flow...
On the weekly chart a LABU / LABD ratio is plotted with anchored VWAP bands and a volume profile overlaid. I wanted to analyze this to affirm the highest of prospects for the Biotechnology sector for 2024. LABU is triple leveraged Up while LABD is the inverse Down. A good unleveraged biotech ETF is XBI. The chart shows LABU in a VWAP band and breakout ...
XBI, the S&Ps Biotech ETF has been ranging nicely just below a major pivot that has acted as resistance for over two years. Bounced off the 20 EMA on the daily and made a beautiful candle on Friday. Anything that happens below $95 must be taken with a grain of salt, but it looks like it wants to breakout and flip that resistance pivot to support.
Neurocrine Biosciences, a mid cap pharmaceutical firm is up for earnings on February 7th. Investor and trader interest seems to be moderately increasing in the past week. The combined MACD / RSI indicator is bullish. This looks good for a longtrade to be taken in the premarket before 7:45 AM as earnings report at 8:00
RYTM did a 120% run in November and December and then pivoted to start the year. It competes in the anti-obesity drug space which is all the rage right now and has snack food manufactures freaking out. The retrace was a shallow one in a sign of strength finding support at the 0.382 retracement level and then pivoting into a reversal in the past week. The dual...
NBIX Stock Breaks All-Time Highs: A Strong Buy Opportunity Emerges Neurocrine Biosciences Inc. (NBIX) is currently making waves in the stock market as it breaks out of its all-time highs, signaling a promising opportunity for investors. After 14 years of steady upward momentum and price consolidation, NBIX appears poised for further growth, with technical...
Both biotech ETF's AMEX:XBI and NASDAQ:IBB are showing tremendous weakness in the face of a strong market. I suspect that when the market is ready to pullback it may take this a little lower especially in the face of a strong TVC:DXY / Dollar Index. Good luck traders!
Looking at the micro data, we have an uptrend where we're following along the rising bottom. Looking a bit further out, we can see we're in a bullish wedge. General trends say that this will come up, and the company will have only good news about their trials progressing which will drive the price higher. Very near to $2 by the end of February, and we could...
MGNX as a biotech company makes antibodies against certain cancers. The antibody is tagged to chemotherapy molecules and then heads off looking for cancer cells to which it has a strong affinity. So much for the science. MGNX just got upgraded and the new target is $ 16.00 about 25% upside. Biotech and healthcare are projected hot sectors this year. On the...
Can see this at $15.00 given that is where most shares are currently held, according to FRVP; this means there will likely be little downwards price pressure until then. Biotech is generally bearish outside of select, short-lived bull runs - this, in my opinion, creates an opportunity for sentiment arbitrage and is my reasoning for the trade (short term/long term...